Printer Friendly

Chugai and Taisho to Co-Develop and Market Antiresorptive Bisphosphonate R484.

Tokyo, Japan, Sept 13, 2006 - (JCN) - Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. have agreed to co-develop and market antiresorptive bisphosphonate R484, (generic name: ibandronic acid) for treatment of osteoporosis in post-menopausal women.

Under the agreement, Chugai will receive an upfront fee and milestone payments from Taisho.

R484 is currently in phase II clinical trials in Japan and is expected to be the next generation osteoporosis treatment drug. It is marketed under the brand name Bonviva in the U.S.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Sep 13, 2006
Words:92
Previous Article:Dainippon to Launch IC Shelf System.
Next Article:Toppan to Release IC Circulation Management System.
Topics:


Related Articles
Astellas and Toyama Chemical Announce Basic Licensing Agreement on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811.
Chugai Files NDA for an Anti-Tumor Agent, Erlotinib (Epidermal Growth Factor Receptor (EGFR/HER1) Tyrosine Kinase Inhibitor).
Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on...
Chugai Announces Co-Development and Co-Marketing Agreement with Taisho Pharmaceutical for the Antiresorptive Bisphosphonate R484.
Chugai to Launch HIV Protease Inhibitor INVIRASE(R) Tablet 500mg on September 15.
Chugai Pharmaceutical to Establish an Oncology Unit.
Eisai Lawsuit Against Generic Drug Manufacturers Dismissed.
Anti-Cancer Agent Avastin(R) Approved in Japan.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters